🚀 VC round data is live in beta, check it out!
Inhibrx Biosciences Overview
About Inhibrx Biosciences
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Founded
2024
HQ
Employees
161
Website
Sectors
Financials (LTM)
EV
$1B
Inhibrx Biosciences Financials
Inhibrx Biosciences reported last 12-month revenue of $944K.
In the same LTM period, Inhibrx Biosciences generated had net loss of ($139M).
Revenue (LTM)
Inhibrx Biosciences P&L
In the most recent fiscal year, Inhibrx Biosciences reported revenue of $1M and EBITDA of ($125M).
Inhibrx Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $944K | XXX | $1M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($125M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (9644%) | XXX | XXX | XXX |
| EBIT Margin | (15364%) | XXX | (10387%) | XXX | XXX | XXX |
| Net Profit | ($139M) | XXX | ($140M) | XXX | XXX | XXX |
| Net Margin | (14705%) | XXX | (10773%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Inhibrx Biosciences Stock Performance
Inhibrx Biosciences has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Inhibrx Biosciences' stock price is $75.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 12.8% | XXX | XXX | XXX | $-9.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInhibrx Biosciences Valuation Multiples
Inhibrx Biosciences trades at 1154.1x EV/Revenue multiple, and (8.7x) EV/EBITDA.
EV / Revenue (LTM)
Inhibrx Biosciences Financial Valuation Multiples
As of April 11, 2026, Inhibrx Biosciences has market cap of $1B and EV of $1B.
Equity research analysts estimate Inhibrx Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inhibrx Biosciences has a P/E ratio of (8.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1154.1x | XXX | 837.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.7x) | XXX | XXX | XXX |
| EV/EBIT | (7.5x) | XXX | (8.1x) | XXX | XXX | XXX |
| P/E | (8.0x) | XXX | (7.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Inhibrx Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Inhibrx Biosciences Margins & Growth Rates
Inhibrx Biosciences' revenue in the last 12 month grew by 1560%.
Inhibrx Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
Inhibrx Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1560% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (9644%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (107%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2677% | XXX | 1792% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11488% | XXX | 8694% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10487% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Inhibrx Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Inventiva | XXX | XXX | XXX | XXX | XXX | XXX |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Septerna | XXX | XXX | XXX | XXX | XXX | XXX |
| Idorsia | XXX | XXX | XXX | XXX | XXX | XXX |
| Neuren Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inhibrx Biosciences M&A Activity
Inhibrx Biosciences acquired XXX companies to date.
Last acquisition by Inhibrx Biosciences was on XXXXXXXX, XXXXX. Inhibrx Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Inhibrx Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInhibrx Biosciences Investment Activity
Inhibrx Biosciences invested in XXX companies to date.
Inhibrx Biosciences made its latest investment on XXXXXXXX, XXXXX. Inhibrx Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Inhibrx Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Inhibrx Biosciences
| When was Inhibrx Biosciences founded? | Inhibrx Biosciences was founded in 2024. |
| Where is Inhibrx Biosciences headquartered? | Inhibrx Biosciences is headquartered in United States. |
| How many employees does Inhibrx Biosciences have? | As of today, Inhibrx Biosciences has over 161 employees. |
| Who is the CEO of Inhibrx Biosciences? | Inhibrx Biosciences' CEO is Mark Paul Lappe. |
| Is Inhibrx Biosciences publicly listed? | Yes, Inhibrx Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Inhibrx Biosciences? | Inhibrx Biosciences trades under INBX ticker. |
| When did Inhibrx Biosciences go public? | Inhibrx Biosciences went public in 2024. |
| Who are competitors of Inhibrx Biosciences? | Inhibrx Biosciences main competitors are Inventiva, GNI Group, Septerna, Idorsia. |
| What is the current market cap of Inhibrx Biosciences? | Inhibrx Biosciences' current market cap is $1B. |
| What is the current revenue of Inhibrx Biosciences? | Inhibrx Biosciences' last 12 months revenue is $944K. |
| What is the current revenue growth of Inhibrx Biosciences? | Inhibrx Biosciences revenue growth (NTM/LTM) is 1560%. |
| What is the current EV/Revenue multiple of Inhibrx Biosciences? | Current revenue multiple of Inhibrx Biosciences is 1154.1x. |
| Is Inhibrx Biosciences profitable? | No, Inhibrx Biosciences is not profitable. |
| What is the current net income of Inhibrx Biosciences? | Inhibrx Biosciences' last 12 months net income is ($139M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.